



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

October 17, 2025

Corporate Relationship Department
BSE Ltd.
Mumbai 400 001

Manager – Listing
National Stock Exchange of India Ltd
Mumbai 400 051

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Earlier intimation dated October 9, 2025

With reference to the above cited subject, please find enclosed herewith the Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Legal update regarding Risdiplam**Hyderabad, India, October 17th, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today updates on the legal proceedings on Risdiplam in India**

With reference to earlier update on 9th October 2025, the Commercial Appellate Division of the Hon'ble Delhi High Court, in the Risdiplam suit, was challenged by the Swiss Pharmaceutical Company F. Hoffmann-La Roche AG before the Supreme Court of India. The Apex Court took note of the concurrent findings of the Ld. Single Judge as well as the Division Bench of the Delhi High Court in denying injunctions against NATCO Pharma Limited. Having the benefit of the two successive orders, the Supreme Court was not convinced about the maintainability of the challenge by Roche and, therefore, dismissed the petition. This marks the final challenge Roche could have posed at the interim stage in the suit, which shall now proceed for trial in accordance with the law. Senior Advocate J. Sai Deepak appeared for NATCO before the Learned Single Judge and Division Bench of the Hon'ble Delhi High Court and was assisted by the counsels on record S. Majumdar and Co. In the Supreme Court, NATCO was represented by Senior Advocates Kapil Sibal, Gopal Subramaniam and J. Sai Deepak and were instructed by S. Majumdar and Co and KMNP Law.

Spinal Muscular Atrophy (SMA) is one of the leading causes of death in infants related to the degeneration of neurons. Currently, there are no curative treatment options for SMA, and most of the available options are not financially feasible for Indian patients. This ruling would bring some hope to the countless lives that have been debilitated by an ailment like SMA.

About NATCO Pharma Limited

NATCO Pharma Limited, (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company's differentiated manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com.



NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

For further information or queries please contact:

Rajeev Menon – Manager, Investor Relations
Email: ir@natcopharma.co.in

Rajesh Chebiyam – EVP, Crop Health Sciences
Email: investors@natcopharma.co.in

Tel: 040-23547532 / Ext – 323

Follow us on:

X (formerly Twitter): https://twitter.com/pharma_natco

LinkedIn: <https://www.linkedin.com/company/natcopharma>